Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alimera Sciences to Release First Quarter 2015 Financial Results

ALIM

ATLANTA, April 28, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter 2015 financial results after the market close on Thursday, May 7, 2015. An investor conference call will follow on the same day at 4:30 p.m. ET.

Dan Myers, President and Chief Executive Officer, and Rick Eiswirth, Chief Operating Officer and Chief Financial Officer, will host the conference call, during which they will discuss the results and provide commercial and other business updates.

To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or (253) 237-1165 (international). A live webcast will be available on the Investor Relations section of the corporate website at http://www.alimerasciences.com.   

A replay of the conference call will be available beginning May 7, 2015 at 7:30 p.m. ET and ending on May 14, 2015 by dialing (855) 859-2056   (U.S. and Canada) or (404) 537-3406   (international), Conference ID Number: 35589901. A replay of the webcast will also be available on the corporate website.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera's European operations are conducted from London by its subsidiary, Alimera Sciences Limited, which has offices in Aldershot, U.K., Berlin, Germany and Lisbon, Portugal.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alimera-sciences-to-release-first-quarter-2015-financial-results-300073713.html

SOURCE Alimera Sciences, Inc.